By Sean Marshall
Next month is Sickle cell awareness month and the writer at ACJ.com aren’t wasting any time in reminding people what is happening during the month of September. It was reported that the Sickle Cell Foundation of Georgia is hosting a “Sickle Cell Candlelight Vigil at 3p.m. on September 2 at the Georgia State Capital. 206 Washington St.”
The vigil is a planned event that is intended to bring public attention to sickle cell disease and remind the community that it still is a deadly disease. According to The Sickle Cell Foundation of Georgia there are still “affects about 100,000 people in the United States.”
Lastly the foundation wanted the public to know that it is also planning to host “another event, Walk-A-Mile for Sickle Cell, beginning at 9 a.m. Sept. 19 at its office, 2391 Benjamin E. Mays Dr .”
The original article can be found below: http://www.ajc.com/news/lifestyles/health/sickle-cell-month-launches-series-of-events/nnNfD/
Other news this week included a research report that Mast Therapeutics Inc is expected to “announce phase 3 data in Sickle Cell Crisis for its lead drug 188.” It was explained that the drug 188 could “benefit numerous pathologies in SCD, especially vaso-occlusive crises (VOC).”
There were some down sides it was mentioned despite strong clinical benefits the data misses statistical significance. This was blamed on “the difficulty of enrolling SCD crises trials.” The article did go over the stock ratings over the company for those who were interested in investing capital.
Original article can be found here:
If there are any comments questions or concerns email us at the firstname.lastname@example.org
Leave a Reply.
This section is solely to let our Sickle Soldiers tell their story trials & tribulations alongside things they feel are wrong in the Sickle Cell Community